1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Overall recanalization rates per treatment protocol
StudyNo RecanalizationPartial RecanalizationComplete Recanalization
Study 1 (IA reteplase and MDT), n = 476 (13%)27 (57%)14 (30%)
Study 2 (EKOS), n = 12a1 (10%)*4 (40%)*5 (50%)*
Study 3 (IV thrombolysis and MDT) n = 196 (32%)8 (42%)5 (26%)
Study 4 (IV abciximab and IA reteplase) n = 136 (46%)2 (15%)5 (39%)
  • * Data were missing for 2 patients; percentages are of 10 patients.